Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Biomea Fusion Q3 2026 Results: Net Loss of $6.18M, Loss Narrows

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for diabetes and obesity. The filing indicates substantial doubt about the company's ability to continue as a going concern, highlighting a critical need for additional capital to fund ongoing research and development of its lead candidates, icovamenib and BMF-650.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-6.2-16.4
EPS (diluted, $ a share)$-0.09$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BMEA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biomea Fusion, Inc.: key numbers

Share price
$0.4880Close, Nov 17
Market cap
$35.5M
Shares outstanding
72.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biomea Fusion, Inc.

All →
4:28 PM ET 8-K
Financial Results

Biomea Fusion Financial Results

Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.

Term
Q3 2026

“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer

“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer
6:00 AM ET 8-K
Clinical Trial Data

Biomea Fusion Clinical Trial Data

Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.

4:02 PM ET 8-K
Clinical Trial Data

Biomea Fusion Clinical Trial Data

Biomea Fusion updated the anticipated timing for topline results from its Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The company now expects to release the data in October 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.